⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30187800 | 1.00 | — | — | |
| SCHEMBL29457227 | 0.81 | — | — | |
| SCHEMBL359435 | 0.81 | — | — | |
| SCHEMBL29457228 | 0.81 | — | — | |
| SCHEMBL28735939 | 0.77 | — | — | |
| SCHEMBL15749443 | 0.77 | — | — | |
| SCHEMBL16997464 | 0.75 | — | — | |
| SCHEMBL31564702 | 0.75 | — | — | |
| SCHEMBL31444505 | 0.75 | — | — | |
| SCHEMBL4713024 | 0.75 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 76 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260115199-A1 | TRICYCLIC COMPOUNDS FOR THE TREATMENT OF CANCER | HOFFMANN-LA ROCHE INC. (US) | 2026-04-30 | — | — | US | disclosed |
| EP-4658662-A1 | MACROCYCLIC AMINOPYRIDINE COMPOUNDS AS EGFR INHIBITORS | Yuhan Corporation (KR) | 2025-12-10 | — | — | EP | disclosed |
| EP-4655304-A1 | MACROCYCLIC AMINOPYRIDINE COMPOUNDS AS EGFR INHIBITORS | Yuhan Corporation (KR) | 2025-12-03 | — | — | EP | disclosed |
| US-20250270190-A1 | KIT INHIBITORS | BLUEPRINT MEDICINES CORPORATION | 2025-08-28 | — | — | US | disclosed |
| WO-2025079989-A1 | PYRAZOLO[3,4-B]PYRIDINE DERIVATIVE OR SALT THEREOF, AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | 주식회사유한양행 | 2025-04-17 | — | — | WO | disclosed |
| US-12258327-B2 | 5-membered heteroaryl-containing aminopyridine compounds as EGFR inhibitors | YUHAN CORPORATION (KR) | 2025-03-25 | — | — | US | disclosed |
| US-12258328-B2 | 6-membered heteroaryl-containing aminopyridine compounds as EGFR inhibitors | YUHAN CORPORATION (KR) | 2025-03-25 | — | — | US | disclosed |
| CN-119585250-A | KIT inhibitors | 蓝图药品公司 | 2025-03-07 | — | — | CN | disclosed |
| EP-4511366-A1 | KIT INHIBITORS | Blueprint Medicines Corporation (US) | 2025-02-26 | — | — | EP | disclosed |
| US-20250034187-A1 | STING AGONISTIC COMPOUND | ONO PHARMACEUTICAL CO., LTD. (JP) | 2025-01-30 | — | — | US | disclosed |
| CN-112566915-A | Thiadiazole IRAK4 inhibitor | 吉利德科学公司 | 2021-03-26 | — | — | CN | disclosed |
| CN-112533924-A | Pyrrolo [1,2-b ] pyridazine derivatives as IRAK4 inhibitors | 吉利德科学公司 | 2021-03-19 | — | — | CN | disclosed |
| US-20200079769-A1 | THIADIAZOLE IRAK4 COMPOUNDS | GILEAD SCIENCES, INC. | 2020-03-12 | — | — | US | disclosed |
| CN-110818641-A | Pyridazine-3-formamide compound, preparation method and application thereof in medicine and pharmacology | 北京诺诚健华医药科技有限公司 | 2020-02-21 | — | — | CN | disclosed |
| WO-2020036830-A1 | PYRROLO[1,2-B]PYRIDAZINE DERIVATIVES AS IRAK4 INHIBITORS | GILEAD SCIENCES, INC. (US) | 2020-02-20 | — | — | WO | disclosed |
| WO-2020036986-A1 | THIADIAZOLE IRAK4 INHIBITORS | GILEAD SCIENCES, INC. (US) | 2020-02-20 | — | — | WO | disclosed |
| WO-2020036986-A1 | THIADIAZOLE IRAK4 INHIBITORS | GILEAD SCIENCES, INC. (US) | 2020-02-20 | — | — | WO | disclosed |
| US-20200048261-A1 | PYRROLO[1,2-b]PYRIDAZINE DERIVATIVES | GILEAD SCIENCES, INC. (US) | 2020-02-13 | — | — | US | disclosed |
| US-20200048261-A1 | PYRROLO[1,2-b]PYRIDAZINE DERIVATIVES | GILEAD SCIENCES, INC. (US) | 2020-02-13 | — | — | US | disclosed |
| WO-2012044567-A2 | IMIDAZOLE DERIVATIVES | MERCK SHARP & DOHME CORP. (US) | 2012-04-05 | — | — | WO | disclosed |